Retracted studies had relied on health-record analyses from a company that declined to share its raw data for an audit. Two weeks after a high-profile paper in The Lancet1 reported that the antimalarial drug hydroxychloroquine might be dangerous to patients with COVID-19, three of its four authors have retracted the work because they were unable to independently verify their data set, a large proprietary collection of electronic health records analysed by Surgisphere, a US company. On the same day, 4 June, the researchers and other co-authors retracted a paper in the New England Journal of Medicine (NEJM)2, for the same reason. That study, published a month ago, had looked at the impact of certain heart medications on people with COVID-19, and found no safety concerns.

 

 

Ragesoss CC BY-SA 4.0 (https://creativecommons.org/licenses/by-sa/4.0)], from Wikimedia Commons

Read more…